Skip to main content
SpringerLink
Log in

Understanding therapeutic targets in thrombotic thrombocytopenic purpura

  • Understanding the Disease
  • Published:
Intensive Care Medicine Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Furlan M, Robles R, Galbusera M et al (1998) von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 339:1578–1584

    Article  CAS  PubMed  Google Scholar 

  2. Tsai HM, Lian EC (1998) Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 339:1585–1594

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Zheng XL (2015) ADAMTS13 and von Willebrand factor in thrombotic thrombocytopenic purpura. Annu Rev Med 66:211–225

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Pillai VF, Bao J, Zander CB et al (2016) Human neutrophil peptides inhibit cleavage of von Willebrand factor by ADAMTS13: a potential link of inflammation to TTP. Blood 128:110–119

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Sadler JE (2015) What’s new in the diagnosis and pathophysiology of thrombotic thrombocytopenic purpura. Am Soc Hematol Educ Progr 2015:631–636

    Google Scholar 

  6. Mannucci PM (2015) Understanding organ dysfunction in thrombotic thrombocytopenic purpura. Intensive Care Med 41:715–718

    Article  PubMed  Google Scholar 

  7. Mariotte E, Azoulay E, Galicier L et al (2016) Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathy. Lancet Haematol 3:e237–e245

    Article  PubMed  Google Scholar 

  8. Joly BS, Stepanian A, Leblanc T et al (2016) Child-onset and adolescent-onset acquired thrombotic thrombocytopenic purpura with severe ADAMTS13 deficiency: a cohort study of the French national registry for thrombotic microangiopathy. Lancet Haematol. doi:10.1016/S2352-3026(16)30125-9

    PubMed  Google Scholar 

  9. Rock GA, Shumak KH, Buskard NA et al (1991) Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian apheresis study group. N Engl J Med 325:393–397

    Article  CAS  PubMed  Google Scholar 

  10. Plaimauer B, Kremer Hovinga JA, Juno C et al (2011) Recombinant ADAMTS13 normalizes von Willebrand factor-cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies. J Thromb Haemost 9:936–944

    Article  CAS  PubMed  Google Scholar 

  11. Vanhoorelbeke K, De Meyer SF (2013) Animal models for thrombotic thrombocytopenic purpura. J Thromb Haemost 11:2–10

    Article  PubMed  Google Scholar 

  12. Cai P, Luo H, Xu H et al (2015) Recombinant ADAMTS13 attenuates brain injury after intracerebral hemorrhage. Stroke 46:2647–2653

    Article  CAS  PubMed  Google Scholar 

  13. Sayani FA, Abrams CS (2015) How I treat refractory thrombotic thrombocytopenic purpura. Blood 125:3860–3867

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Scully M, Knoebl P, Kentouche K et al (2016) Pharmacodynamic profile of a recombinant ADAMTS13 (BAX930) in hereditary thrombotic thrombocytopenic purpura [Upshaw-Schulman syndrome (USS)]. Blood 128:135

    Google Scholar 

  15. George JN (2012) Corticosteroids and rituximab as adjunctive treatments for thrombotic thrombocytopenic purpura. Am J Hematol 87(Suppl. 1):S88–S91

    Article  CAS  PubMed  Google Scholar 

  16. Jilma-Stohlawetz P, Gorczyca ME, Jilma B et al (2011) Inhibition of von Willebrand factor by ARC1779 in patients with acute thrombotic thrombocytopenic purpura. Thromb Haemost 105:545–552

    Article  CAS  PubMed  Google Scholar 

  17. Peyvandi F, Scully M, Kremer Hovinga JA et al (2016) Caplacizumab for acquired thrombotic thrombocytopenic purpura. N Engl J Med 374:511–522

    Article  CAS  PubMed  Google Scholar 

  18. Chen J, Reheman A, Gushiken FC et al (2011) N-acetylcysteine reduces the size and activity of von Willebrand factor in human plasma and mice. J Clin Investig 12:593–603

    Article  Google Scholar 

  19. Jian C, Xiao J, Gong L et al (2012) Gain-of-function ADAMTS13 variants that are resistant to autoantibodies against ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura. Blood 119:3836–3843

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service d’hématologie biologique and EA3518-Institut universitaire d’hématologie, Groupe Hospitalier Saint Louis-Lariboisière, Assistance Publique-Hôpitaux de Paris, Université Paris Diderot, 2 rue Ambroise Paré, 75010, Paris, France

    Bérangère S. Joly & Agnès Veyradier

  2. Laboratory for Thrombosis Research, IRF Life Sciences, KU Leuven Campus Kulak Kortrijk, Kortrijk, Belgium

    Karen Vanhoorelbeke

Authors
  1. Bérangère S. Joly
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Karen Vanhoorelbeke
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Agnès Veyradier
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Agnès Veyradier.

Ethics declarations

Conflicts of interest

On behalf of all authors, the corresponding author states that there is no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Joly, B.S., Vanhoorelbeke, K. & Veyradier, A. Understanding therapeutic targets in thrombotic thrombocytopenic purpura. Intensive Care Med 43, 1398–1400 (2017). https://doi.org/10.1007/s00134-016-4662-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00134-016-4662-3

Keywords

Search

Navigation